Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01533493 · ClinicalTrials.gov registry record · NA
Memantine for Executive Dysfunction in Adults With ADHD: A Pilot Study
A NA study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- NA
- Development phase
- 33
- Enrollment target
NCT01533493: Completed NA study, sponsored by Massachusetts General Hospital.
NCT01533493 is a NA study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 33 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01533493, a NA study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- NA
- Development phase
- 33 participants
- Enrollment target
Study Summary
This is a 12-week clinical trial evaluating the efficacy and safety of memantine hydrochloride (Namenda) in the treatment of executive function deficits (EFDs) in adults with Attention Deficit Hyperactivity Disorder (ADHD) receiving open-label treatment with OROS-Methylphenidate (OROS-MPH, Concerta). The study aims to examine the effects of treatment with memantine on ADHD symptoms. Following screening procedures, memantine is prescribed in randomized, double-blind fashion (equal chance of medication or placebo) for 12 weeks, along with open-label OROS-MPH (everyone receives medication).
Interventions
- DRUG Placebo
- DRUG Memantine Hydrochloride
- DRUG OROS-Methylphenidate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2012-05 |
| Est. Completion | 2013-08 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01533493
The ClinicalTrials.gov registry entry for NCT01533493 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01533493 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01533493 about?
NCT01533493 is a clinical study titled "Memantine for Executive Dysfunction in Adults With ADHD: A Pilot Study". This is a 12-week clinical trial evaluating the efficacy and safety of memantine hydrochloride (Namenda) in the treatment of executive function deficits (EFDs) in adults with Attention Deficit Hyperactivity Disorder (ADHD) receiving open-label treatment with OROS-Methylphenidate (OROS-MPH, Concerta)...
What is the current status of trial NCT01533493?
This trial is currently completed. It is a NA study. The enrollment target is 33 participants. The study started on 2012-05. Estimated completion is 2013-08.
What interventions are being tested in trial NCT01533493?
The interventions under investigation include: Placebo (DRUG), Memantine Hydrochloride (DRUG), OROS-Methylphenidate (DRUG).
Who is sponsoring clinical trial NCT01533493?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.